Gain Contingency, Number of Patents Being Challenged

No definition available.

Name:	pfe_GainContingencyNumberOfPatentsBeingChallenged
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Number of Cases Settled

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyNumberOfCasesSettled
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalid
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Under Review

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsUnderReview
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Site Contingency, Regulatory Proceedings, Disclosure Threshold

+ References

No definition available.

+ Details

Name:	pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_LitigationCaseAxis=pfe_VyndaqelLitigationCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_MicroLabsChangzhouAndBioconPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXEuropeanPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ArbutusAndGenevantUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_BayerCropscienceLLCMonsantoCompanyAndMonsantoTechnologyLLCUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_SanofiUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions	1 Months Ended									12 Months Ended
	Jul. 31, 2026 patent	Apr. 30, 2026 case	Mar. 29, 2026 patent	Jan. 31, 2026 patent	Sep. 28, 2025 patent	Jul. 31, 2025 patent	Mar. 30, 2025 patent	Aug. 31, 2024 patent	Apr. 30, 2024 patent	Dec. 31, 2024 patent	Dec. 31, 2023 patent	Dec. 31, 2022 patent	Jun. 28, 2026 USD ($)
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws \| $													$ 1
Vyndaqel Litigation Case [Member]
Gain Contingencies [Line Items]
Number of cases settled \| case		3
Micro Labs, Changzhou and Biocon Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents being challenged			3
Comirnaty [Member] \| ModernaTX U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon												3
Loss contingency, patents under review										2
Loss contingency, patents ruled invalid							2
Comirnaty [Member] \| ModernaTX European Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon										2		2
Loss contingency, patents ruled invalid and subsequently revoked										1
Comirnaty [Member] \| Arbutus and Genevant U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon											5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon								3	5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon						3
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon					3
Comirnaty [Member] \| Bayer Cropscience LLC, Monsanto Company and Monsanto Technology, LLC US Patent Infringement Case
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon				1
Comirnaty [Member] \| Sanofi US Patent Infringement Case \| Subsequent Event [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon	8